Abbott Laboratories (NYSE: ABT) is praised as one of the best slow-growth stocks to invest in. UBS maintains a Buy rating and $158 price target following Abbott’s acquisition of Exact Sciences. This deal marks the largest acquisition in the medtech sector this year, with Abbott set to purchase Exact Sciences at $105 per share, boosting its Diagnostics division by 300 basis points. The acquisition allows Abbott to expand its medical device business into cancer care, including Exact Sciences’ Cologuard test for colorectal cancer. UBS predicts Abbott will outperform competitors in sales and earnings per share from 2026 onwards due to its strong medical technology profile and consistent growth. Abbott Laboratories is a prominent global healthcare company known for its diverse range of products, including medications, medical devices, diagnostics, and nutritional items. While Abbott presents investment potential, some believe that certain AI stocks offer greater upside with less risk. Check out our free report on the best short-term AI stock for more information.

Read more at Yahoo Finance: UBS Reaffirms Buy Rating on Abbott Laboratories (ABT) Amid Exact Sciences Acquisition